Sliesoraitis Sarunas, Tawfik Bernard
Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157-0001.
J Am Osteopath Assoc. 2011 Jul;111(7):437-41.
Bevacizumab has shown efficacy in many different malignancies and is approved by the US Food and Drug Administration for advanced colon and lung cancers. As bevacizumab use is expanding, the number of reports of serious adverse effects from the drug are growing. Bowel perforation is a rare but often fatal event that leads the list of dangerous adverse effects. It has been frequently reported in ovarian cancer trials, with early closure of some trials because of the high incidence of bowel perforation. Physicians should be familiar with not only the presentation of bowel perforation, but also with the risk factors, considerations for surgery, and management of perforation in selected patient populations. The authors review the current knowledge on bevacizumab-induced bowel perforation.
贝伐单抗已在多种不同的恶性肿瘤中显示出疗效，并被美国食品药品监督管理局批准用于晚期结肠癌和肺癌。随着贝伐单抗使用范围的扩大，该药物严重不良反应的报告数量也在增加。肠穿孔是一种罕见但通常致命的事件，在危险的不良反应中位居前列。它在卵巢癌试验中经常被报道，一些试验因肠穿孔发生率高而提前终止。医生不仅应熟悉肠穿孔的表现，还应了解危险因素、手术考量以及特定患者群体中穿孔的处理方法。作者回顾了目前关于贝伐单抗所致肠穿孔的知识。
